Article Text

Download PDFPDF
Liraglutide does not provide sustainable results for weight improvement in adolescents with obesity
  1. Clare Brady1,
  2. M Guftar Shaikh2
  1. 1General Paediatrics, Royal Hospital for Children, Glasgow, UK
  2. 2Endocrinology, Royal Hospital for Sick Children, Glasgow, Glasgow, UK
  1. Correspondence to Dr Clare Brady, General paediatrics, Royal Hospital for Children, Glasgow G51 4TF, UK; c.brady1{at}nhs.net

Statistics from Altmetric.com

Review ofKelly AS, Auerbach P, Barrientos-Perez M, et al. A randomised, controlled trial of liraglutide for adolescents with obesity. N Engl J Med 2020 May;382:2117–2128. DOI: 10.1056/nejmoa1916038.

Allocation: Central randomisation using a web-based response system. Randomisation was stratified according to pubertal status and glycaemic status.

Setting: 32 sites over five countries (Belgium, Mexico, Russia, Sweden and the USA).

Intervention: All participants received lifestyle therapy. 125 were assigned to liraglutide and 126 assigned to the placebo group, receiving a volume matched equivalent.

Patients: 251 participants, aged 12 to <18 years. All participants were obese (defined as body mass index (BMI) of 30 or more), stable body weight (self-reported change of less than 5 kg during the 90 days before screening) and poor response …

View Full Text

Footnotes

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.